Botox Receives National Marketing Authorization to Treat Crow's-Feet Lines

Today, Allergan, Inc. announced that Botox has received the license from the Medicines and Healthcare products Regulatory Agency (MHRA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines (crow's-feet lines) seen at maximum smile, either alone or when treated at the same time as glabellar (or frown) lines seen at maximum frown, in adult patients where these facial lines have an important psychological impact. This marketing authorization is specific to Allergan's botulinum toxin type A product and is based on Allergan's successful global Phase III clinical trial program in crow's-feet lines.

"This latest approval for Botox demonstrates Allergan's continued commitment to excellence in neuromodulator innovation and our long-term leadership in medical esthetics," said Paul Navarre, president of Allergan Europe, Africa & Middle East. "We are proud to deliver this important innovation to medical esthetics practitioners in the United Kingdom, allowing them for the first time to treat the glabellar and crow's-feet areas either alone or simultaneously."

Great news for BOTOX!  It has just received the license from the Medicines and Healthcare products Regulatory Agency (MHRA) for the temporary improvement in the appearance of moderate to severe Crow's Feet, meaning that this stuff really works! To read the entire article click here.


© Allergan, Ltd. BOTOX® is a registered trademark owned by Allergan Inc.